An interventional study of Red/green glasses and Electronic Tablet in Amblyopia, sponsored by Universidad Autonoma de Nuevo Leon. Recruiting at 1 site in Mexico. Open to participants aged 4 Years to 10 Years. Per ClinicalTrials.gov, last updated 2026-05-06.
Sponsored by Universidad Autonoma de Nuevo Leon · Not applicable, Interventional, and Treatment
Amblyopia, or lazy eye, is best defined by the American Academy of Ophthalmology as a unilateral or bilateral reduction of the best corrected visual acuity that occurs in the setting of an otherwise normal eye, or a structural abnormality involving the eye or visual pathway with reduction in visual acuity that cannot be attributed only to the effect of the structural abnormality. Which causes an abnormal visual experience early in life, with consequences such as deficiencies in the ability to perceive contrast and/or movement, visual acuity, accommodation and stereopsis. The treatment of choice consists in patching of the fellow eye 2 hours per day. The disadvantage of this treatment modality is that patients end up not complying and when treatment is interrupted, lazy eye reappears. Amblyopia was thought to be a monocular disease, now a days there are reports of cortical visual paths changes in both eyes (the fellow and amblyopia eye), believing that it might be a monocular consequence of a binocular disease. Following that statement new treatment studies have arisen, stimulating both eyes not only to improve visual acuity in the lazy eye, but to restore binocular function as well. These treatments use videogames in celular phones, computers, or tablets where the fellow eye is exposed to reduced contrast and the lazy eye is exposed to full-contrast. Although the evidence is promising, more studies are needed to establish effectivity and security of this treatment modality.
The objective of this study is to determine if the binocular visual therapy with red-green glasses and the use of electronic devices is effective for amblyopia treatment in children.
Participants will be randomly assigned to one of three treatment modalities: Group A: eye patch on the fellow eye and to near-vision activities (such as reading, drawing, etc) Group B: an eye patch on the fellow eye and a electronic tablet Group C: red/green glasses and a electronic tablet
Treatment will be done buy the three groups daily during 2 consecutive hours, and will be completed for four months. Children will then suspend the therapy for 2 months, and will be reevaluated to determine lazy eye relapses . All groups will be compared to see which patients achieved greater improvement on visual acuity and depth perception.
189 studies on the registry are indexed under Amblyopia; 41 are open to participants now.
This study's planned enrollment of 60 is close to the median of 60 across 137 interventional studies indexed under Amblyopia.
Browse Amblyopia studies →Universidad Autonoma de Nuevo Leon is the lead sponsor of 53 studies on the registry; 12 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Eye patch on the fellow eye and to near-vision activities (such as reading, drawing, etc)
Device: Eye patch
Eye patch on the fellow eye and a electronic tablet
Device: Electronic Tablet
Red/green glasses and a electronic tablet
Device: Red/green glasses
The use of red/green glasses and electronic devices for two hours a day during 4 months.
The use of eye patch on the fellow eye and electronic tablet for 2 hours a day during 4 months.
The use of eye patch on the fellow eye and near vision activities for 2 hours a day during 4 months.
Best corrected visual acuity of the amblyopic eye
Best corrected visual acuity of the amblyopic eye using the Snellen chart. Measurements will be converted to LogMar values for statistical analysis.
Time frame: Basal
Best corrected visual acuity of the amblyopic eye
Best corrected visual acuity of the amblyopic eye using the Snellen chart. Measurements will be converted to LogMar values for statistical analysis.
Time frame: One month of treatment
Best corrected visual acuity of the amblyopic eye
Best corrected visual acuity of the amblyopic eye using the Snellen chart. Measurements will be converted to LogMar values for statistical analysis.
Time frame: Two months of treatment
Best corrected visual acuity of the amblyopic eye
Best corrected visual acuity of the amblyopic eye using the Snellen chart. Measurements will be converted to LogMar values for statistical analysis.
Time frame: Three months of treatment
Best corrected visual acuity of the amblyopic eye
Best corrected visual acuity of the amblyopic eye using the Snellen chart. Measurements will be converted to LogMar values for statistical analysis.
Time frame: Four months of treatment
Best corrected visual acuity of the amblyopic eye two months after treatment suspension to determine lazy eye relapses
Best corrected visual acuity of the amblyopic eye using the Snellen chart. Measurements will be converted to LogMar values for statistical analysis.
Time frame: Two months after treatment suspension.
Stereopsis
Stereopsis measurement by titmus test
Time frame: Basal
Stereopsis
Stereopsis measurement by titmus test
Time frame: One month of treatment
Stereopsis
Stereopsis measurement by titmus test
Time frame: Two months of treatment
Stereopsis
Stereopsis measurement by titmus test
Time frame: Three months of treatment
Stereopsis
Stereopsis measurement by titmus test
Time frame: Four months of treatment
Stereopsis two months after treatment suspension to determine lazy eye relapses
Stereopsis measurement by titmus test
Time frame: Two months after treatment suspension.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Universidad Autonoma de Nuevo Leon